Evidence map›Paper›PMID 42568736›Full record

ArticleJTO clinical and research reports2026

Development and Characterization of a Patient-Derived

Akihiro Nishiyama, Shigeki Sato, Hiroyuki Sakaguchi, Hiroshi Kotani, Kaname Yamashita, Koushiro Ohtsubo, Shigeki Nanjo, Seiji Yano, Keishi Mizuguchi, Hiroko Ikeda and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Akihiro NishiyamaDepartment of Medical Oncology, Kanazawa University Hospital, Kanazawa, Japan.
Shigeki SatoDepartment of Medical Oncology, Kanazawa University Hospital, Kanazawa, Japan.
Hiroyuki SakaguchiDepartment of Medical Oncology, Kanazawa University Hospital, Kanazawa, Japan.
Hiroshi KotaniDepartment of Medical Oncology, Kanazawa University Hospital, Kanazawa, Japan.
Kaname YamashitaDepartment of Medical Oncology, Kanazawa University Hospital, Kanazawa, Japan.
Koushiro OhtsuboDepartment of Medical Oncology, Kanazawa University Hospital, Kanazawa, Japan.
Shigeki NanjoDepartment of Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Japan.
Seiji YanoDepartment of Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Japan.
Keishi MizuguchiDepartment of Diagnostic Pathology, Kanazawa University Hospital, Kanazawa, Japan.
Hiroko IkedaDepartment of Diagnostic Pathology, Kanazawa University Hospital, Kanazawa, Japan.
Makiko YamaguchiDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.
Tamotsu IshizukaDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.
Satoko BabaDivision of Pathology, Cancer Institute, Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Kengo TakeuchiDepartment of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Shinji TakeuchiDepartment of Medical Oncology, Kanazawa University Hospital, Kanazawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This study presents the development and characterization of a novel lung adenocarcinoma cell line with kinesin family member 5B rearranged during transfection ( Methods: A pleural effusion sample was collected from a patient with Results: The newly established PB302 cell line has the following three key characteristics: high sensitivity to selective Conclusions: This cell line highlights several potentials as a tool for preclinical research and drug development.

Indexed as

Central nervous system disease modelKIF5B-RET fusionPatient-derived cell lineSelective RET tyrosine kinase inhibitorSubcutaneous tumor model

Identifiers

PMID42568736
PMCPMC13447563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.